rimtuzalcap (CAD-1883) / Saniona, Novartis - LARVOL DELTA

Structural basis for the subtype-selectivity of KCa2.2 channel activators. (PubMed, Res Sq) - "Calmodulin's N-lobes in the K Ca 3.1 structure are closer to each other and are constrained by the HC helices of K Ca 3.1, which allows binding of NS309 but not of the bulkier rimtuzalcap. These structures provide a framework for structure-based drug design targeting K Ca 2.2 channels."

Journal • Ataxia • Essential Tremor • Movement Disorders

Synchrony-1: Study of CAD-1883 for Spinocerebellar Ataxia (clinicaltrials.gov) - P2; N=0; Withdrawn; Sponsor: Cadent Therapeutics; N=48 ➔ 0; Suspended ➔ Withdrawn

Clinical • Enrollment change • Trial withdrawal • Ataxia • Movement Disorders

Saniona received approximately USD $2.9 million (SEK 24.2 million) upfront payment in connection with Cadent Therapeutics transaction (Streetinsider.com) - "Saniona...today announced it received approximately USD $2.9 million (SEK 24.2 million) in an upfront payment resulting from the now completed acquisition of Cadent Therapeutics by a third party. Saniona holds an ownership stake of approximately 3% in Cadent Therapeutics resulting from Cadent’s previous acquisition of the Saniona spin-out Ataxion...In connection with Saniona’s license agreement with Cadent, Saniona is also entitled to receive royalties on any potential products developed and commercialized...including CAD-1883...advanced into Phase 2 clinical trials and which may have potential in movement disorders."

Commercial • Ataxia • CNS Disorders • Essential Tremor

Cadent Therapeutics enters agreement to be acquired by Novartis (Cadent Therapeutics Press Release) - "Cadent Therapeutics...announced today that it has reached a definitive agreement with Novartis, under which Novartis will acquire all of the outstanding capital stock of Cadent Therapeutics. Upon the closing of the agreement, Cadent will receive a $210 million upfront payment and will be eligible for up to $560 million in milestone payments, for a total potential consideration of $770 million....Additionally, Novartis will gain full rights to CAD-1883, a clinical stage SK channel positive allosteric modulator in development for movement disorders."

M&A • CNS Disorders • Essential Tremor

Synchrony-1: Study of CAD-1883 for Spinocerebellar Ataxia (clinicaltrials.gov) - P2; N=48; Suspended; Sponsor: Cadent Therapeutics; Trial completion date: Dec 2021 ➔ Dec 2022; Initiation date: Aug 2020 ➔ Jun 2021; Trial primary completion date: Nov 2021 ➔ Nov 2022

Clinical • Trial completion date • Trial initiation date • Trial primary completion date • Ataxia • Movement Disorders • CASP3

Synchrony-1: Study of CAD-1883 for Spinocerebellar Ataxia (clinicaltrials.gov) - P2; N=48; Suspended; Sponsor: Cadent Therapeutics; Trial completion date: Jul 2021 ➔ Dec 2021; Initiation date: Mar 2020 ➔ Aug 2020; Recruiting ➔ Suspended; Trial primary completion date: Jun 2021 ➔ Nov 2021

Clinical • Trial completion date • Trial initiation date • Trial primary completion date • Trial suspension • CASP3

Synchrony-1: Phase 2 Study of CAD-1883 for Spinocerebellar Ataxia (clinicaltrials.gov) - P2; N=48; Recruiting; Sponsor: Cadent Therapeutics

Clinical • New P2 trial • CASP3

Phase 2a Open-Label Study to Evaluate the Safety, Tolerability and Efficacy of CAD-1883 in Essential Tremor (Cadence-1) (MDS-PAS 2020) - "CAD-1883 was well tolerated in this Phase 2a study. An increase in mean exposure coincided with a larger improvement in the TETRAS-PS score for Cohort 2 compared to Cohort 1. A larger, controlled study is warranted to confirm this efficacy signal."

Clinical • Late-breaking abstract • P2a data

Cadent Therapeutics announces poster presentation at the 3rd Pan American Parkinson’s Disease and Movement Disorders Congress (Cadent Therapeutics Press Release) - P2a, N=NA; "Cadent Therapeutics...today announced that the Company’s Cadence-1 study will be highlighted in a poster presentation at the 3rd Pan American Parkinson’s Disease and Movement Disorders Congress from February 14-16, 2020 at the InterContinental Miami in Miami, Florida."

P2a data

Cadent Therapeutics announces FDA acceptance of IND application for CAD-1883 for spinocerebellar ataxia (SCA) (Businesswire) - "Cadent Therapeutics...today announced the U.S. Food and Drug Administration (FDA) has accepted its Investigational New Drug (IND) application to initiate a Phase 2 clinical trial for CAD-1883...for the treatment of spinocerebellar ataxia (SCA). 'The FDA acceptance of our second IND application for CAD-1883 signifies another important milestone for Cadent' stated Jodie Morrison, Chief Executive Officer, 'With our clinical proof of concept (POC) data in hand for the SK channel, we now look forward to driving to Phase 2 efficacy data in our lead indication of SCA...' "

IND • P2 data

A Clinical Study to Evaluate CAD-1883 in Essential Tremor (clinicaltrials.gov) - P2a; N=25; Completed; Sponsor: Cadent Therapeutics; Recruiting ➔ Completed; Trial completion date: Jan 2020 ➔ Sep 2019

Clinical • Trial completion • Trial completion date

"ET Treatments in Pipeline CAD1883 https://t.co/2YrIXN3lWE SAGE 324 https://t.co/kzSFEYCtuA CX 8998 https://t.co/LoQsdqxPbE" (@jillfarmmovedoc)

A Clinical Study to Evaluate CAD-1883 in Essential Tremor (clinicaltrials.gov) - P2a; N=30; Recruiting; Sponsor: Cadent Therapeutics; N=20 ➔ 30; Trial completion date: Sep 2019 ➔ Jan 2020; Trial primary completion date: Aug 2019 ➔ Dec 2019

Clinical • Enrollment change • Trial completion date • Trial primary completion date